ProteoMedix, a Switzerland-based prostate cancer diagnostics spinout from ETH Zurich, obtained CHF5.2m ($5.3m) on Monday in a round led by venture capital firm Altos Ventures.

Canton of Zurich-owned financial services firm Zürcher Kantonalbank took part in the round, together with assorted angel investors.

Founded in 2010, ProteoMedix develops medical products for the diagnosis and prognosis of prostate cancer.

The spinout’s lead project is a blood-based test for a protein biomarker, linked to the cancerous PI3K/PTEN pathway, which could help clarify…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?